Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A; Carvedilol Or Metoprolol European Trial Investigators. Poole-Wilson PA, et al. Among authors: hanrath p. Lancet. 2003 Jul 5;362(9377):7-13. doi: 10.1016/S0140-6736(03)13800-7. Lancet. 2003. PMID: 12853193 Clinical Trial.
A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET).
Cleland JG, Goode K, Erhardt L, Remme WJ, Charlesworth A, Poole-Wilson PA, Di Lenarda A, Hanrath P, Komajda M, Metra M, Swedberg K, Torp-Pedersen C; Carvedilol or Metoprolol European Trial Investigators. Cleland JG, et al. Among authors: hanrath p. Cardiovasc Drugs Ther. 2004 Mar;18(2):139-52. doi: 10.1023/B:CARD.0000029032.46744.56. Cardiovasc Drugs Ther. 2004. PMID: 15162076 Clinical Trial.
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Torp-Pedersen C, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lutiger B, Metra M, Remme WJ, Scherhag A, Skene A; COMET Investigators. Torp-Pedersen C, et al. Among authors: hanrath p. Am Heart J. 2005 Feb;149(2):370-6. doi: 10.1016/j.ahj.2004.10.002. Am Heart J. 2005. PMID: 15846279 Clinical Trial.
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials.
Metra M, Eichhorn E, Abraham WT, Linseman J, Böhm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR; ESSENTIAL Investigators. Metra M, et al. Eur Heart J. 2009 Dec;30(24):3015-26. doi: 10.1093/eurheartj/ehp338. Eur Heart J. 2009. PMID: 19700774 Free PMC article. Clinical Trial.
Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects.
McClean DR, Ikram H, Mehta S, Heywood JT, Rousseau MF, Niederman AL, Sequeira RF, Fleck E, Singh SN, Coutu B, Hanrath P, Komajda M, Bryson CC, Qian C, Hanyok JJ; Omapatrilat Hemodynamic Study Group. McClean DR, et al. Among authors: hanrath p. J Am Coll Cardiol. 2002 Jun 19;39(12):2034-41. doi: 10.1016/s0735-1097(02)01881-8. J Am Coll Cardiol. 2002. PMID: 12084605 Free article. Clinical Trial.
506 results